{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-062068","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.817461+00:00","generated_at":"2026-06-18T09:47:01.171416+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Seres Therapeutics reports FY2022 net loss $250.2M, SER-109 PDUFA date April 26, 2023","bullets":["FY2022 net loss $250.2M vs $65.6M in FY2021; Q4 net loss $68.8M vs $50.0M.","Cash & equivalents $181.3M at Dec 31, 2022, down from $291.2M at end of 2021.","SER-109 BLA under FDA priority review with PDUFA target action date April 26, 2023; commercial launch anticipated soon after.","SER-155 Phase 1b: cohort 2 enrollment ongoing; initial safety/pharmacology data from cohort 1 expected May 2023.","Pending FDA approval, Seres expects $125M milestone payment from Nestlé Health Science."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-062068","json":"https://secwatch.observer/filing/0001193125-23-062068.json","markdown":"https://secwatch.observer/filing/0001193125-23-062068.md","text":"https://secwatch.observer/filing/0001193125-23-062068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523062068/0001193125-23-062068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523062068/d448387d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:47:01.171416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d0c499bdcdc1a02bae79b37ed3c9c02780448ab3","claim":"Seres Therapeutics, Inc. reported financial results for quarter and year ended December 31, 2022.","evidence_excerpt":"On March 7, 2023, Seres Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022 and provided operational updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523062068/0001193125-23-062068-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}